Dynavax Technologies Corp
NASDAQ:DVAX
Dynavax Technologies Corp
Gross Profit
Dynavax Technologies Corp
Gross Profit Peer Comparison
Competitive Gross Profit Analysis
Latest Figures & CAGR of Competitors
Company | Gross Profit | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Dynavax Technologies Corp
NASDAQ:DVAX
|
Gross Profit
$189.7m
|
CAGR 3-Years
31%
|
CAGR 5-Years
106%
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Gross Profit
$36.1B
|
CAGR 3-Years
3%
|
CAGR 5-Years
7%
|
CAGR 10-Years
10%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Gross Profit
$20.8B
|
CAGR 3-Years
0%
|
CAGR 5-Years
4%
|
CAGR 10-Years
7%
|
|
Amgen Inc
NASDAQ:AMGN
|
Gross Profit
$19.6B
|
CAGR 3-Years
1%
|
CAGR 5-Years
0%
|
CAGR 10-Years
3%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Gross Profit
$8.8B
|
CAGR 3-Years
16%
|
CAGR 5-Years
26%
|
CAGR 10-Years
26%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Gross Profit
$11.3B
|
CAGR 3-Years
12%
|
CAGR 5-Years
13%
|
CAGR 10-Years
18%
|
See Also
What is Dynavax Technologies Corp's Gross Profit?
Gross Profit
189.7m
USD
Based on the financial report for Mar 31, 2024, Dynavax Technologies Corp's Gross Profit amounts to 189.7m USD.
What is Dynavax Technologies Corp's Gross Profit growth rate?
Gross Profit CAGR 5Y
106%
Over the last year, the Gross Profit growth was -55%. The average annual Gross Profit growth rates for Dynavax Technologies Corp have been 31% over the past three years , 106% over the past five years .